Engineering Conferences International

ECI Digital Archives
Vaccine Technology VIII

Proceedings

6-12-2022

Process development for a flexible vaccine vector platform based
on recombinant life virus
Dieter Palmberger,
Shirin Preinsperger
Willibald Steinfellner
Matthias Müllner
Alois Jungbauer

See next page for additional authors

Follow this and additional works at: https://dc.engconfintl.org/vaccine_viii

Authors
Dieter Palmberger,; Shirin Preinsperger; Willibald Steinfellner; Matthias Müllner; Alois Jungbauer; and
Kerstin Rumpelmayr

PROCESS DEVELOPMENT FOR A FLEXIBLE VACCINE VECTOR PLATFORM BASED ON RECOMBINANT
LIFE VIRUS
Dieter Palmberger, Themis Bioscience GmbH, a subsidiary of Merck & Co., Inc.
dieter.palmberger@merck.com
Shirin Preinsperger, acib – austrian centre of industrial biotechnology
Willibald Steinfellner, acib – austrian centre of industrial biotechnology
Matthias Müllner, Themis Bioscience GmbH, a subsidiary of Merck & Co., Inc.
Alois Jungbauer, University of Natural Resources and Life Sciences, Vienna
Kerstin Rumpelmayr, Themis Bioscience GmbH, a subsidiary of Merck & Co., Inc.
Key Words:

Life virus, Vaccines, Platform technology.

Vaccines are one of the most important, safe and efficient interventions to protect people from illness, disability
and death. In recent years several new viral outbreaks where no vaccines are currently available were reported
worldwide. Therefore, the development of flexible processes for the production of vaccines is urgently needed.
This project aims at developing a platform process for the production of different viral vaccines. The core
technology is based on the fact that large recombinant genes coding for selected, foreign antigens can be
inserted into the genome of a well-established virus vaccination vector. The vaccine delivers the selected
antigens directly to macrophages and dendritic cells, the most potent and effective antigen-presenting cells,
thereby triggering a specific immune response to the selected antigens. As a replicating vector, the vaccine
continuously expresses antigens even after immunization. This setup results in a powerful, antigen-focused
immune response, which is expected to confer long-term immunity.
The challenges in production process design for such a vaccine are the establishment of a robust cell expansion
and infection strategy as well the development of efficient downstream processing methods including several
chromatography principals, ultra-diafiltration and employment of bio recognition principles. The implementation
of a meaningful monitoring/characterization concept furthermore serves as a basis for reliable in-process control
strategies.
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